SCHEMBL1748714

SCHEMBL1748714

COc1cc2c(-c3cc4c(Cl)ccnc4[nH]3)cn(C)c2cc1OCCN1CCC(N2CCCCC2)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 2/20 0.47
HRH3 Q9Y5N1 4/20 0.41
EPHA2 P29317 2/20 0.40
KDR P35968 2/20 0.40
EPHB4 P54760 2/20 0.40
CDK9 P50750 4/20 0.39
CCNT1 O60563 3/20 0.39
EGFR P00533 2/20 0.38
TLR9 Q9NR96 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
JAK2 O60674 1/20 0.37
LCK P06239 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37
CDK7 P50613 1/20 0.37
BTK Q06187 1/20 0.37
LRRK2 Q5S007 1/20 0.37
AURKB Q96GD4 1/20 0.37
EHMT2 Q96KQ7 3/20 0.36
EHMT1 Q9H9B1 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5797454 0.97 IGF1R (0.45) IGF1RHRH3EPHA2KDREPHB4
SCHEMBL1748700 0.87 IGF1R (0.53) IGF1REPHA2KDREPHB4EGFR
SCHEMBL5795300 0.87 IGF1R (0.47) IGF1REPHA2KDREPHB4CDK9
SCHEMBL4493773 0.86 IGF1R (0.46) IGF1REPHA2KDREPHB4CDK9
SCHEMBL4496734 0.85 IGF1R (0.49) IGF1REPHA2KDREPHB4CDK9
SCHEMBL1749105 0.85 IGF1R (0.51) IGF1RHRH3CDK9CCNT1JAK2
SCHEMBL1748784 0.84 IGF1R (0.50) IGF1REPHA2KDREPHB4CDK9
Pyridine SCHEMBL5795805 0.83 IGF1R (0.51) IGF1REPHA2KDREPHB4EGFR
SCHEMBL5797459 0.82 IGF1R (0.42) IGF1REPHA2KDREPHB4CDK9
SCHEMBL1748713 0.82 IGF1R (0.46) IGF1REPHA2KDREPHB4CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US claimed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US claimed
US-7968566-B2 Pyrrolo(2,3-b) pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2011-06-28 US disclosed
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS AVENTIS PHARMA S.A. (FR) 2009-09-17 US disclosed
US-7528147-B2 Pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2009-05-05 US disclosed
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors AVENTIS PHARMA S.A. (FR) 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233956-A1 NOVEL PYRROLO(2,3-b) PYRIDINE DERIVATIVES, THE PREPARATION AND THE PHARMACEUTICAL USE THEREOF IN THE FORM OF KINASE INHIBITORS MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885HRH3 1501/4885EPHA2 1440/4885
US-20070093480-A1 Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors MAP3K19, MAP4K2, MAP3K1 IGF1R 817/4885HRH3 1501/4885EPHA2 1440/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.